The Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference took place at the Moscone Center in San Francisco, USA from October 23 – 26, 2023. Here are our top highlights of TCT 2023.
In a prior analysis of the PARTNER 3 Low-Risk study, it was found that low-risk patients with severe, symptomatic aortic stenosis had a significantly lower rate of the combined outcome of death, stroke, or rehospitalization at one year when treated with transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement. At TCT 2023, investigators presented 5 year outcomes. A total of 1000 patients were randomized to undergo TAVR (n = 503) or surgery (n = 497). These results were simultaneously published in the New England Journal of Medicine and concluded that in the case of low-risk patients with severe, symptomatic aortic stenosis who underwent either TAVR or surgery, there were no significant between the two groups in terms of the primary combined outcomes.
The 4-year findings from the EVOLUT Low Risk trial, simultaneously published the Journal of American College of Cardiology, showed a persistent trend indicating lower combined rates of all-cause mortality and disabling stroke with transcatheter aortic valve implantation (TAVI) in comparison to surgical aortic valve replacement (SAVR) (10.7% vs. 14.1%, p=0.05).
The ALIGN-AR trial examined patients with severe aortic regurgitation (AR) at high surgical risk. It focused on the use of the JenaValve Trilogy transcatheter heart valve (THV) in transcatheter aortic valve replacement (TAVR). The trial involved........